{"url_path":"/sec/lbrx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1691082/0001193125-26-219607-index.html","accession_number":"0001193125-26-219607","cik":"0001691082","ticker":"LBRX","issuer_name":"LB PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1691082/0001193125-26-219607-index.html","primary_entity_key":"0001691082","primary_entity_name":"LB PHARMACEUTICALS INC"},"word_count":341,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\nFurnish the exhibits required by Item 601 of Regulation S-K (§ 229.601 of this chapter).\n\n \n\n \n\n \n\n \n\nIncorporated by Reference\n\nExhibit\n\nNumber\n\n \n\nDescription\n\nForm\n\nFile No.\n\nExhibit\n\nFiling Date\n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation of the Registrant.](https://www.sec.gov/Archives/edgar/data/1691082/000119312525202195/d32696dex31.htm)\n\n8-K\n\n001-42831\n\n3.1\n\nSeptember 12, 2025\n\n3.2\n\n \n\n[Amended and Restated Bylaws of the Registrant.](https://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex34.htm)\n\nS-1\n\n333-289812\n\n3.4\n\nAugust 22, 2025\n\n31.1*\n\n \n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](lbrx-ex31_1.htm)\n\n \n\n \n\n \n\n \n\n31.2*\n\n \n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](lbrx-ex31_2.htm)\n\n \n\n \n\n \n\n \n\n32.1*+\n\n \n\n[Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](lbrx-ex32_1.htm)\n\n \n\n \n\n \n\n \n\n101.INS\n\n \n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n \n\n \n\n \n\n \n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n \n\n \n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n \n\n* Filed herewith.\n\n+ These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.\n\n \n\n86\n\n[Table of Contents](#toc_page)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nLB Pharmaceuticals Inc\n\nDate: May 12, 2026\n\nBy:\n\n/s/ Heather Turner\n\nHeather Turner\n\nChief Executive Officer\n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\nDate: May 12, 2026\n\nBy:\n\n/s/ Marc Panoff\n\n \n\n \n\n \n\nMarc Panoff\n\n \n\n \n\n \n\nSenior Vice President, Finance\n\n \n\n \n\n \n\n(Principal Financial and Accounting Officer)\n\n \n\n87"}